ArticlePatient preference and adherence2016

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan.

Naoya Masumori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.